- Previous Close
1.1400 - Open
1.1400 - Bid 1.1100 x --
- Ask 1.1200 x --
- Day's Range
1.0800 - 1.1400 - 52 Week Range
0.9800 - 2.0800 - Volume
67,107 - Avg. Volume
142,637 - Market Cap (intraday)
85.552M - Beta (5Y Monthly) 1.51
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3600 - Earnings Date Mar 5, 2025 - Mar 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.75
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
www.oncolyticsbiotech.comRecent News: ONC.TO
View MorePerformance Overview: ONC.TO
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONC.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONC.TO
View MoreValuation Measures
Market Cap
87.86M
Enterprise Value
69.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.70
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-71.33%
Return on Equity (ttm)
-138.22%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-28.02M
Diluted EPS (ttm)
-0.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
24.85M
Total Debt/Equity (mrq)
6.09%
Levered Free Cash Flow (ttm)
-15.77M